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ABSTRACT 
 
Adenylyl cyclases are a ubiquitous family of enzymes and are critical regulators of metabolic 
and cardiovascular function.   Multiple isoforms of the enzyme are expressed in a range of 
tissues.  However, for many processes the adenylyl cyclase isoforms have been thought of as 
essentially interchangeable, with their impact more dependent on their common actions to 
increase intracellular cAMP content regardless of the isoform involved.  It has long been 
appreciated that each subfamily of isoforms demonstrate a specific pattern of  “upstream” 
regulation, i.e., specific patterns of ion dependence (e.g., calcium-dependence) and specific 
patterns of regulation by kinases (PKA, PKC, raf).  However, more recent studies have suggested 
that adenylyl cyclase isoform-selective patterns of signaling are a wide-spread phenomenon.  
The determinants of these selective signaling patterns relate to a number of factors, including: i) 
selective coupling of specific adenylyl cyclase isoforms with specific GPCRs, ii) localization of 
specific adenylyl cyclase isoforms in defined structural domains (AKAP complexes, 
caveolin/lipid rafts) and iii) selective coupling of adenylyl cyclase isoforms with specific 
downstream signaling cascades important in regulation of cell growth and contractility.  The 
importance of isoform-specific regulation has now been demonstrated both in mouse models as 
well as in humans. 
Adenylyl cyclase has not been viewed as a useful target for therapeutic regulation, given 
the ubiquitous expression of the enzyme and the perceived high risk of off-target effects.  
Understanding which isoforms of adenylyl cyclase mediate distinct cellular effects would bring 
new significance  to the development of  isoform-specific ligands to regulate discrete cellular 
actions.  
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INTRODUCTION 
The adenylyl cyclases are a ubiquitously expressed family of enzymes that catalyze the 
generation of cyclic adenosine monophosphate (cAMP) from adenosine triphosphate (ATP).  
Adenylyl cyclases regulate a broad range of cellular functions (Cooper et al., 1995, Hanoune and 
Defer, 2001, Patel et al., 2001).  These enzymes are critical effectors for a number of G protein–
coupled receptors (GPCRs).  Adenylyl cyclase activation has been suggested to be the rate-
limiting step in the GPCR signaling cascade (Ostrom et al., 2000).  
The adenylyl cyclases have been extensively and perhaps even exhaustively studied.  
Since their initial descriptions in the 1960’s more than 20,000 papers have been published that 
include the search terms adenylyl/adenylate cyclase or cyclic AMP, including almost 700 reviews.  
Further, the field of adenylyl cyclases/cAMP biology has been the basis of 3 Nobel Prize awards 
include those of Earl Sutherland (1971), Ed Fischer/Ed Krebs (1992) and Al Gilman/Marty 
Rodbell (1994).  Thus, in 2011 it might be reasonable to ask whether there is anything new that a 
reader could expect to glean from yet another review in this very well-tilled field of research.  In 
this short review we would like to focus on two aspects of cAMP/adenylyl cyclase biology that 
are perhaps less appreciated but critical for the understanding of this crucial second messenger 
system. 
The basis of this brief review will be to discuss and dispel a widely held but probably 
untenable belief about the basic workings of this system, viz. that because of the ubiquity of 
adenylyl cyclases and the very common effects of all isoforms of the family, the development of 
therapeutic strategies based on isoform-selective regulation is a “fool’s errand”.  In contrast to this 
widely-held belief, the major focus of this review will be to highlight that: 
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1) The effects mediated by adenylyl cyclase isoforms are critically dependent on the isoform-
selective “signalosomes” in which they are situated, and 
2) Regulation of specific isoforms would be expected (and do) have significant impact on 
cardiovascular and respiratory regulation 
 
ADENYLYL CYCLASE ISOFORMS AND ISOFORM-SPECIFIC REGULATION 
Adenylyl cyclases comprise a family of nine membrane-bound isoforms grouped into 3 
major subfamilies, comprising: Group 1: AC1, AC3, AC8, Group 2: AC2, AC4, AC7 and Group 
3: AC5, AC6 (Patel et al., 2001).  Additionally, AC9 has been characterized as a distinct (and 
atypical) isoform(Premont et al., 1996)(Sunahara and Taussig, 2002) with restricted expression, 
and a soluble adenylyl cyclase has been characterized that is the predominant form in mammalian 
sperm (Wuttke et al., 2001). Each isoform has a specific pattern of tissue/organ distribution and a 
specific pattern of regulation by G proteins, calcium/calmodulin, and protein kinases (Thomas and 
Hoffman, 1996, Harry et al., 1997, Wang and Brown, 2004). For example, Raf kinases regulate 
AC2, AC5 and AC6, whereas they do not regulate AC1 (Ding et al., 2004) (Table 1). 
      The distribution of adenylyl cyclase isoforms varies between tissues (Cooper, 2003).  
Further, the effects of adenylyl cyclase activation in regulating several cellular functions, 
including cell growth, qualitatively differ between tissues (Lee et al., 2001, Wong et al., 2001).   
Although there are multiple G protein-dependent mechanisms regulating the function of 
adenylyl cyclase, it has been believed that the consequence of activation of any of the isoforms is 
singular (i.e., that cAMP generation mediates the same effect regardless of the isoform involved in 
the process).  However, recent studies have suggested that there are many important examples of 
isoform-specific signaling especially in regulation of cardiovascular and respiratory function.  
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These relate in part, to the organization of specific adenylyl cyclase isoforms in distinct cellular 
compartments and (perhaps consequently) association of specific adenylyl cyclase isoforms with 
specific G protein coupled receptor/G protein complexes as well as with particular downstream 
effectors. 
 
ADENYLYL CYCLASE COMPARTMENTATION MODELS 
Adenylyl cyclase isoforms have been localized in several structural cellular compartments.  
The best characterized are their association with caveolar and lipid raft microdomains and in 
complexes with A-kinase anchoring proteins (AKAPs)(Dessauer, 2009). 
Specific receptors, adenylyl cyclase isoforms and downstream effectors are targeted to 
lipid rafts and/or caveolae, creating discrete signaling compartments that allow common signaling 
pathways to generate a variety of situation-specific responses.  A number of studies have 
demonstrated AC isoform-specific coupling to specific GPCR’s, and this coupling reflects the co-
localization of receptors and given AC isoforms in lipid rafts.  Overexpression of AC6 in rat 
neonatal myocytes enhances cAMP production in response to the ß-adrenergic receptor (ßAR) 
agonist isoproterenol without affecting response to stimulation of other Gαs-coupled receptors 
such as adenosine A2, histamine H2 and glucagon receptors (Ostrom et al., 2000). This selective 
coupling is seemingly explained by the observation that AC6 colocalizes with ßAR in 
caveolae/lipid rafts in rat neonatal ventricular myocytes but other GPCR are excluded from these 
domains. AC6 more efficiently couples to ß1AR than ß2AR in these cells, likely due to 4-fold 
higher expression of ß1AR and movement of ß2AR out of caveolae following activation (Ostrom 
et al., 2001). 
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In human bronchial smooth muscle cells, ßAR preferentially signals via activation of AC6, 
which coexists with ß2AR in lipid rafts (Bogard et al., 2011). In these same cells EP2R act through 
ßγ-stimulable, and calcium insensitive, cyclases (AC2 and AC4) that are expressed exclusinvely 
in non-raft fractions of the plasma membrane.  Thus, ACs appear to have isoform-specific 
localization with respect tor lipid rafts and non-raft domains and this feature is consistent across 
many cell types (Fagan et al., 2000, Ostrom et al., 2000, Ostrom et al., 2002, Smith et al., 2002, 
Ostrom and Insel, 2004).   Such compartmentation in plasma membrane microdomains appears 
responsible, in part, for the observed selective coupling between GPCR and specific adenylyl 
cyclase isoforms. 
Notably, preferential coupling of specific adenylyl cyclase isoforms with specific receptors 
may be regulatable- adding an additional level of complexity.  In uterine smooth muscle, α2 
adrenoceptors switch from being adenylyl cyclase inhibitory to stimulatory during mid-term 
pregnancy (Zhou et al., 2000).  Subsequent studies demonstrated that upregulation of AC2 and the 
consequent switch in α2 adrenoceptors effects on adenylyl cyclase activity being predominantly 
mediated through this isoform being the most likely responsible mechanism (Zhou et al., 2007). 
Whether this shift  parallels a change in compartmentation of either receptor or adenylyl cyclase 
isoforms remains to be determined. 
In addition to placing specific AC isoforms and receptors in close proximity, lipid rafts 
appear to play a role in cyclase regulation by capacitative calcium entry (CCE).  AC6 is inhibited 
by CCE but not calcium from intracellular stores or ionophore-mediated entry (Cooper et al., 
1995).   The fast Ca2+ chelator BAPTA is able to block CCE impact on cyclase activity, but 
EGTA, a chelator with similar affinity but slower binding rate, has no effect on cAMP production 
(Fagan et al., 1998).  The lack of EGTA effect suggests AC is located near sites of CCE.   
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Disrupting lipid rafts removes CCE regulation of AC6 without affecting CCE itself, and these 
features return upon lipid raft restoration (Fagan et al., 2000).  Lipid rafts seem important for 
association of calcium–sensitive cyclases and sites of CCE, while the cytoskeleton does not 
appear to play a role since disruption of the cytoskeleton by a number of compounds does not 
affect the ability of CCE to inhibit Ca-sensitive AC (Fagan et al., 1998). 
Studies of numerous cell types make clear that AC isoforms are stratified as either lipid 
raft localized or non-raft localized (Ostrom and Insel, 2004).  One then wonders how ACs are 
localized in these respective lipid domains. Protein-lipid interactions, protein-protein interactions 
and post-translational modifications are all likely mechanisms. This question has been examined 
using a number of different approaches. Two separate studies have revealed the importance of the 
intracellular C1 and C2 domains in targeting adenylyl cyclase to lipid rafts.  Crossthwaite et al. 
made several chimeric proteins combining various portions of raft localized AC5 and non-raft 
AC7 and found that the intracellular, and not transmembrane domains, direct localization to lipid 
rafts (Crossthwaite et al., 2005).  Thangavel et al. created a series of AC6 fragments and truncated 
proteins (Thangavel et al., 2009).  C1 and C2 fragments of AC6 localize to bouyant fractions and 
co-immunoprecipitate with caveolin-1  (Thangavel et al., 2009).  These studies indicate that the 
transmembrane domains do not play a role in targeting cyclase to lipid rafts, implying that 
interactions with membrane lipids are probably not as important as protein-protein interactions for 
raft localization of these isoforms. 
One protein that is known to localize to caveolae and act as a scaffolding molecule for 
various signaling proteins is caveolin.  Caveolin-1 does not appear to be responsible for anchoring 
cyclases in lipid rafts, since cardiac fibroblasts isolated from cav-1 knockout mice displayed the 
same expression and localization of cyclases (Thangavel et al., 2009).  In addition, HEK-293 cell 
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lines that do not express caveolin proteins still target overexpressed AC6 to lipid rafts (Thangavel 
et al., 2009).     
Although it has been demonstrated that the intracellular domains are enough to target 
cyclase fragments or chimeric proteins to lipid rafts, preventing glycosylation on extracellular 
loops also stops AC8 from localizing to lipid rafts (Pagano et al., 2009). It is possible that 
glycosylation facilitates interaction with proteins that are involved in targeting molecules to lipid 
rafts.  Interestingly, the non-raft localized form of AC8 is still regulated by CCE, and (as with 
native AC8) this regulation is eliminated by MßCD-mediated cholesterol depletion in a reversible 
manner.  Thus, intact lipid rafts are required for CCE regulation of AC activity even when the 
cyclase is not located in them.  
The balance of data indicate that lipid rafts bring together a subset of signaling molecules 
and may facilitate coupling of specific AC isoforms with certain GPCR’s and other signaling 
proteins, helping to direct specific responses.   
Another way cells can bring signaling molecules together for specific pathways and 
regulation is through A Kinase Anchoring Proteins (AKAPs). All AKAPs have a protein kinase A 
(PKA) binding motif that binds the regulatory subunit of PKA, but otherwise they are quite 
variable (Dessauer, 2009). They can be targeted to the plasma membrane or membranes of 
organelles such as golgi, mitochondria or nucleus.  AKAPs act as scaffolds and bring together 
specific combinations of kinases and their substrates as well as other components involved in a 
wide array of signaling pathways. Such scaffolding is important for rapid signal transduction as 
well as rapid termination of signaling. 
AKAPs have recently been shown to interact with cyclases in an isoform-specific 
manner.  The first isoform-specific AC-AKAP interactions were determined only a few years 
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ago (Bauman et al., 2006).  Current research is focused on further uncovering specific AC-
AKAP associations and investigating how participation in AKAP complexes contributes to the 
regulation of AC. 
So far a conserved AC-binding domain has not been found across AKAPs.  Of the sites 
determined to bind AC, there is little similarity among AKAPs, even when they bind the same 
AC isoform (Piggott et al., 2008, Kapiloff et al., 2009).  Different AC isoforms can bind different 
locations on the same AKAP.  The N terminus of AC2 interacts directly with amino acids 808-
957 of the AKAP Yotiao, but AC1, AC3 and AC9 do not interact with this site although they are 
bound by Yotiao (Piggott et al., 2008).  Known AKAP-AC interactions include mAKAP with 
AC2 and AC5 (Kapiloff et al., 2009),  AKAP79/150 with AC2, 3, 5, 6, 8, and 9 (Efendiev et al., 
2010), and AKAP9/Yotiao with AC1, 2, 3, and 9 (Piggott et al., 2008).  
AKAPs can mediate regulation of cAMP-PKA signaling in a number of ways either 
through direct interaction or bringing various components together in a complex.  Interaction of 
AC8 with AKAP 79/150 appears to decrease the cyclase’s sensitivity to Ca2+ (Willoughby et al., 
2010).   Yotiao acts only as a scaffold with no effect on activity of AC1 and AC9 but has an 
inhibitory effect on AC2 and AC3 (Piggott et al., 2008).  The scaffolding of cyclases and PDEs, 
kinases and phosphatases, and kinase-sensitive receptors/cyclases allows tight regulation of 
signaling cascades.   For example, AKAP79/150 interacts with PKA,  ß2AR, and several 
isoforms of AC including AC5 and AC6 (Bauman et al., 2006). Once activated, PKA can 
phosphorylate a number of substrates including ßAR (causing desensitization, G protein 
switching, receptor translocation) and AC (PKA phosphorylation inhibits AC5 and AC6), 
preventing further signaling via feedback inhibition.  Other kinases such as PKC can also be 
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anchored by AKAPs and regulate cyclases in an isoform-specific manner.  PKC phoshorylation 
enhances activity of AC1, 2, 3, 5, and 7, but inhibits AC6 (Table 2).      
The specifc AKAP-AC interactions that are defined and the role they play in 
cardiovascular physiology and pathophysiology has recently been reviewed (Efendiev and 
Dessauer, 2011).  Yotiao is one AKAP whose importance in the heart has been recognized due to 
complications associated with mutations of the KCNQ1 subunit of the slow outward potassium 
channel that prevents its interaction with Yotiao.  When Yotiao with its associated proteins is 
unable to bind the potassium channel, the normal PKA and PP1 phosphorylation and 
dephosphorylation of the channel is disrupted and the duration of the action potential is altered 
(Marx et al., 2002).  The resulting arrhythmias can be lethal.  
Thus, ACs are permanent residents of specialized lipid microdomains where receptors 
may selectively and dynamically participate in assembled singaling complexes. AKAPs are key 
members of such signaling complexes based on their interaction with specific AC isoforms, and 
bring with them PKA as well as a number of other scaffolded signaling partners.  Paralleling 
these structural studies, there is increasing evidence of “functional” consequences of adenylyl 
cyclase compartmentation into isoform-specific adenylyl cyclase “signalosomes” linking these 
enzymes with either specific GPCR/G protein complexes and/or specific adenylyl 
cyclase/downstream effector complexes.  However, it should be emphasized that the link 
between the evidence for these “structural” compartments with any specific functional adenylyl 
cyclase signalosome remains to be established. 
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ADENYLYL CYCLASE ISOFORM-SPECIFIC ASSOCIATION WITH DOWNSTREAM 
EFFECTORS  
Although, it has become increasingly clear that there is adenylyl cyclase isoform-specific 
linkage with “upstream” regulators of enzyme function, the consequence of adenylyl cyclase 
activation was seen as singular, i.e., an increase in intracellular cyclic AMP concentrations and 
activation of its downstream effectors, Exchange Protein Activated by cAMP (Epac) and PKA 
(Cooper et al., 1995, Hanoune and Defer, 2001, Patel et al., 2001).  However, more recent 
evidence has suggested that the linkages between adenylyl cyclase and its proximate effectors 
(Epac and PKA) and more distal responses (growth and contractility) might also be isoform-
specific (Gros et al., 2006). This has perhaps been most clearly demonstrated in vascular smooth 
muscle cells and with the use of adenoviral constructs expressing representative isoforms from the 
subfamilies of adenylyl cyclase, i.e., AC1 and AC3, AC2, AC5, and AC6.  Following expression 
of the isoforms to equivalent levels of both protein content and stimulated catalytic activity (at 
least as assessed in absence of phosphodiesterase activity, see below), isoform-specific 
differences in both growth regulatory and cytoskeletal reorganization processes could be 
demonstrated (Gros et al., 2006).  
 AC6 has been shown to have an isoform-specific effect in regulation of cellular contractile 
responses.  Assessing adenylyl cyclase-mediated cytoskeletal reorganization in vascular smooth 
muscle cells, only expression of AC6 was associated with an enhanced response. This paralleled 
the observation that only AC6 gene transfer enhanced adenylyl cyclase-mediated PKA activation 
as assessed by Vasodilator Stimulated Phosphoprotein (VASP) phosphorylation.  Further, in the 
presence of uninhibited endogenous phosphodiesterase activity, only AC6 expression enhanced 
cAMP accumulation.  Because the AC6 effect on cytoskeletal reorganization was paralleled by an 
AC6-selective uncoupling of cAMP synthesis and breakdown and an AC6-selective effect on 
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phosphorylation of the PKA substrate, VASP, we hypothesized that the AC6 isoform may 
participate in molecular complexes devoid of phosphodiesterase but enriched in PKA/VASP as 
well as in intermediates in cytoskeletal rearrangements (Gros et al., 2006).  Thus differential 
coupling of adenylyl cyclase isoforms with specific cell functions in this setting appeared to be 
best explained by cellular compartmentation of AC6 in a domain distinct from phosphodiesterase 
effects (at least relative to the other isoforms tested). 
 In regards to growth regulatory effects, expression of AC1 resulted in significantly greater 
inhibition of growth vs. both control cells as well as those expressing the other representative 
adenylyl cyclase isoforms.  These isoform-selective growth regulatory effects paralleled the 
selective actions of AC1 expression to increase adenylyl cyclase-stimulated ERK activation vs. 
the effects seen with expression of the other isoforms tested.  Further, a direct association between 
ERK and AC1 (and AC3) could be shown, suggesting that these proteins were part of a structural 
signalosome complex resulting in more efficient isoform-selective regulation of cell growth.  The 
details of this structural complex are yet to be determined.  Notably, in these studies, gene transfer 
of AC1/AC3 was NOT associated with any detectable increase in cAMP concentrations when 
assessed in the presence of uninhibited endogenous phosphodiesterase activity. (Gros et al., 2006)  
These finding could be explained by the efficient compartment-specific channeling of the product 
of adenylyl cyclase activity (i.e., cAMP) in these AC1/3 domains, not detectable in whole cell 
cAMP assays.  However, these data might also suggest that the actions of AC1 and AC3 were a 
consequence of their association with ERK and were cAMP-independent. 
 Recent studies by Gao et al. support the hypothesis that adenylyl cyclase isoforms can 
have physiological effects independent of their cAMP generating function (Gao et al., 2011).  
Expressing a catalytically inactive AC6 mutant in cardiac myocytes, Gao et al. found these cells 
had reduced cellular hypertrophy and apoptosis when challenged with phenylephrine.  These 
responses were similar to those observed when wild type AC6 was overexpressed.  It was 
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hypothesized that in this model, AC6 facilitates formation of a signalasome between discreet 
signaling proteins regulating cell growth.  Whether these effects are AC6 isoform-specific in this 
cell model, analogous to the AC1/3-specific effects on cell growth demonstrated in vascular 
smooth muscle cells, remains to be determined.  However, in aggregate, these studies highlight 
the need to further understand the signaling complexes formed with specific AC isoforms. 
 
ISOFORM-SPECIFIC REGULATION OF ADENYLYL CYCLASE FUNCTION: 
GENETIC APPROACHES 
As noted above, isoform-specific regulation of adenylyl cyclase has been shown in 
several contexts.  However, the functional consequences of such isoform-specific regulation 
have only been more recently appreciated.  Based on knockout mouse models, genetic disruption 
of specific AC isoforms has been associated with specific phenotypical defects.  AC5 disruption 
is associated with increased longevity and protection against stress (Yan et al., 2007) but 
Parkinson-like motor dysfunction (Iwamoto et al., 2003).  Genetic disruption of AC3 impairs 
male fertility and spermatozoon function (Livera et al., 2005) and anosmia (Wong et al., 2000).  
However, whether any of these phenotypes was truly isoform-specific or more generally related 
to the decrease in stimulated adenylyl cyclase activity in the tissues in which these specific 
isoforms predominated could not be determined.  Further, the significance in humans of the 
isoform-specific phenotypes seen in animal models has only begun to be explored. 
Perhaps the most illustrative approach in examining the impact of isoform-specific 
regulation of adenylyl cyclases in humans has utilized missense human genetic AC6 variants.  
The A674S variant of AC6 has been shown to be expressed in whites with an allelic frequency of 
approximately 6% (Gros et al., 2005).  In cell systems, expression of the variant results in 
enhanced adenylyl cyclase activity and adenylyl cyclase-mediated cytoskeletal reorganization 
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(Gros et al., 2007). Further, mononuclear leukocytes from subjects expressing the A674S variant 
possessed increased adenylyl cyclase activity and adenylyl cyclase mediated cellular retraction.  
These cellular indices of enhanced adenylyl cyclase function based on expression of this variant 
paralleled increased potency of ß-adrenergic receptor-mediated vasodilation (Gros et al., 2007). 
Hemodynamically, younger healthy subjects expressing the variant demonstrated increased 
systolic blood pressure, heart rate, cardiac output and increased plasma rennin activity (Hodges 
et al.).  This phenotype supports the hypothesis that physiological regulation of a specific 
isoform (AC6) results in the expression of a hyperkinetic hemodynamic phenotype.  Whether 
those subjects demonstrating genetic variants of other AC isoforms, such as those of the 
AC1/AC3, will display alterations in regulation of cellular growth remains to be determined. 
 
CHALLENGES TO PROGRESS IN THE ELUCIDATION OF ADENYLYL CYCLASE 
SIGNALASOMES. 
Efforts to define the signalosomes for each AC isoform are still in the early stages.  ACs 
are notoriously difficult genes and proteins to work with due to their size, complexity and 
resistance to purification.  ACs express at low levels in cells and the available tools for studying 
the proteins, such as antibodies, are of poor quality.  ACs have sensitive tertiary structures that 
are required for normal activity and regulation, yet they also have long half lives, making siRNA 
knockdown troublesome.  Methods for measuring AC activity have advanced in recent years 
with the development of Epac-based biosensors, including versions that can be targeted to 
subcellular domains.  However, these methods of measuring cAMP still lag the fast and accurate 
spatial detection of calcium fluorophores and suffer from the need to exogenously express the 
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sensor.  Overcoming one or more of these methodological shortcomings will be required for 
even incremental advances in our understanding of AC signalasomes. 
 
SUMMARY 
 Interest in adenylyl cyclase regulation has waned in recent years, perhaps in part related to 
the perspective that the enzyme might not be a useful target for therapeutic regulation given its 
ubiquitous expression and multifunctional importance.  However, recent studies have 
demonstrated that adenylyl cyclase isoforms are compartmentalized both structurally and 
functionally.  These findings raise the potential for development of isoform-specific adenylyl 
cyclase ligands which may have both tissue and functional specificity as therapeutic agents.  
Understanding which isoforms of adenylyl cyclase mediate which cellular effects is bringing new 
significance to the development of isoform-specific ligands to regulate discrete cellular actions. 
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Table 1: 
 
Isoform-specific Regulation of Adenylyl Cyclases 
 
    
Regulator Effect AC subtype References 
    
G protein    
Gs Stimulation All Isoforms (Iyengar, 1993) 
Gi Inhibition ACI, AC5, AC6; not AC2 (Taussig et al., 1993a) 
(Federman et al., 1992) 
(Chen and Iyengar, 1993) 
(Taussig et al., 1994) 
Gßγ  Inhibition AC1, AC5, AC6 (Taussig et al., 1993b) 
(Bayewitch et al., 1998) 
 Stimulation AC2, AC4  
 
Conditional AC5, AC6 
(Tang and Gilman, 1991) 
(Gao and Gilman, 1991) 
(Gao et al., 2007) 
    
Forskolin Stimulation All Isoforms (including AC9) (Onda et al., 2001) 
   (Premont et al., 1996) 
(Cumbay and Watts, 2004) 
Calcium/Calmodulin    
Ca2+/CaM Stimulation AC1, AC3, AC8 (Tang et al., 1991)  
(Choi et al., 1992)  
(Cali et al., 1994) 
Ca2+ Inhibition AC5, AC6 (Yoshimura and Cooper, 
1992) (Katsushika et al., 
1992) 
    
Kinase Regulation    
PKC Stimulation AC1, AC2, AC3, AC5, AC7 (Jacobowitz et al., 1993) 
(Jacobowitz and Iyengar, 
1994) (Bol et al., 1997) 
(Kawabe et al., 1994) 
(Watson et al., 1994) 
 Inhibition AC6 (Lai et al., 1997) 
PKA Inhibition AC5. AC6 (Iwami et al., 1995) 
(Chen et al., 1997) 
CaM Kinase Inhibition AC1. AC3 (Wayman et al., 1996) (Wei 
et al., 1996) 
Raf kinase Stimulation AC2, AC5, AC6      (Ding et al., 2004) 
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Figure:		Schema	of	paradigms	for	isoform-specific	adenylyl	cyclase	compartmentation
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